Replies to post #30749 on Lexaria Bioscience Corp (LEXX)

[Kgem]

Thank you Lanny9 for your civilized post. There is so much going on behind the scenes, but little discussion of it on this board. The press release today is huge --- particularly for European markets. Yet, some talk about a reverse split on this forum that was only mentioned as a last resort if needed to get to a major exchange. I still suggest that Chris is looking at the Amex and nothing lower, but who knows for certain.

The products coming from BAT are in the works right now, and Altria is out in the cold. In my opinion, Altria was not a particularly good deal for LXRP, but the money for research did help greatly.

While I am currently underwater with my first shares, I intend to stick with this investment, and buy even more. Some may think the share price will go further down, but I think the price is going higher. We will see who is right soon enough. I really don't care about short term loses or gains because I am investing in a disruptive technology.



Kgem

[TonyX]

I spoke to IR / Uplisting

I voiced my concerns to Investor Relations
1) Why the hell are they paid so much?
2) Why do they keep raising money that doesn't get spent on the ACTUAL business, but rather just to pay themselves?
3) Why they don't buy shares at these levels if they are so confident?

Regarding uplisting:
The issue I have is that to uplist you need credibility, institutional interest, and a higher stock price (only actual firm guideline)
You know what doesn't help the price? DILUTION
They say they want to uplist but they keep diluting. I'm invested in some other companies that dilute, but they do so in order to invest in the business, this dilution is PURELY to pay themselves. Raising $2mm, spending $00k on R&D and $1.2mm on management who don't seem to do anything. I expressed this as extreme frustration and voiced that this looks like, to an outsider, an insider enrichment scheme and they won't get any traction with reputable firms if this continues.

In my view, unless Bunka spends less on consulting, etc, and more on R&D and partnerships, he has absolutely no intention of building this company or the share price. We will see. I continue to hold, but not for long unless we get some answers that aren't just in the form of "We expect more revenue" or "we have new patents." Patents aren't worth much, they are just ideas and aren't tough to get.

I asked about the estimates of needing $800k for R&D, which they said right before the last raise, but then spent under $400k, the guy told me that was likely to preserve cash so the balance sheet looks good to the NASDAQ. I said this is bullshit, they should have saved that money in salaries of course.

Finally, he said they think the tech can be used in pharma. I responded that if they think that, maybe they should spend money on R&D.